News and Trends 11 Dec 2018 UK Biotech Settles Lawsuit on the First RNAi Drug Silence Therapeutics and Alnylam have reached a settlement that puts an end to a legal dispute between them resulting in Silence receiving some royalties on Onpattro, the first RNA interference… December 11, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Podcast 25 Aug 2023 Beyond Biotech podcast 60 – The cost of research On this week’s podcast, we have a conversation with Dr Jack Scannell, CEO of Etheros Pharmaceuticals Corp. Scannell recently co-authored a paper on the expenses related to clinical research and… August 25, 2023 - 1 minutemin - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Aug 2021 UK Venture Round Shines Spotlight on Europe’s Psychedelics Scene The UK has cemented its position as a European hub for psychedelics research following a €68.5M ($80M) Series B round from the startup Beckley Psytech. The Oxford-based Beckley Psytech —… August 24, 2021 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 28 Apr 2022 OMass Therapeutics Takes on ‘Undruggable’ Proteins with €90M Series B The UK firm OMass Therapeutics has unveiled a €90M (£75.5M) Series B financing to bankroll the development of small molecules against so-called ‘undruggable’ targets, including one that sank Quench Bio… April 28, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jun 2022 New treatment option available for Dravet syndrome Global biopharma company UCB says the UK’s National Institute for Healthcare Excellence (NICE) has issued a positive Final Appraisal Determination (FAD) for its FINTEPLA (fenfluramine) oral solution. FINTEPLA is used… June 1, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Sep 2022 Promising MND drug slows disease progression Scientists in the U.K. believe a new genetically-targeted therapy to treat motor neurone disease (MND) could be a turning point for patient care. Results from a phase 3 clinical trial… September 22, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 Oct 2022 PhoreMost and Arvinas to collaborate on drug discovery against multiple therapeutic targets U.K. biopharma company PhoreMost Ltd. has entered into a multi-target collaboration with Arvinas, a company active in targeted protein degradation (TPD). Under the terms of the agreement, PhoreMost will receive… October 31, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2022 Researchers awarded £2M to develop drugs to prevent epileptic seizures in children Scientists at Aston University in the U.K. have started work on a project that will look for new drug treatments to prevent the onset of childhood epilepsy. The three-year Medical… November 15, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 May 2023 Industry responds to UK science strategy launch The UK Health Security Agency’s (UKHSA) has launched a 10-year science strategy, setting out how science can save more lives and contribute to the U.K.’s ambition of being a global… May 18, 2023 - 7 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Nov 2017 British Biotech Gets Ready to Launch a New Antibiotic Drug to Fight Resistance Update (17/11/2017): Motif Bio will raise up to $20M (€17M) in the form of a loan from US firm Hercules Capital. The funds will be used to fund the pre-commercialization… November 17, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
In Depth 24 Oct 2017 Where to Find the Money to Get Your Biotech Startup Up with the Big Boys What do you need to kickstart your own biotech company? A great idea, of course. Industry knowledge, a plus. Money… This could be tricky. Breaking into the biotech industry is… October 24, 2017 - 8 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 7 Aug 2019 Late-Stage Clinical Trial Troubles for Dry Eye Disease Drug A drug developed by the UK company Topivert Pharma has failed to reduce eyeball grittiness sensations in patients with dry eye disease in a phase II/III trial. The trial tested… August 7, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email